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Ca2+ calcium ion
Chr chromosome
CSF cerebrospinal fluid
CNS central nervous system
CNT control
DS Down’s syndrome
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EndoIII endonuclease III
FAD familial AD
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GPX glutathione peroxidase
h 2o 2 hydrogen peroxide
mAb monoclonal antibody
mtDNA mitochondrial DNA
MMSE Mini-Mental State Examination
nDNA nuclear DNA
NER nucleotide excision repair
NFT neurofibrillary tangle
NF-kB nuclear factor kappa B
OH’ hydroxyl radical
OS oxidative stress
o 2- superoxide anion
PBMC peripheral blood mononuclear cell
PBS phosphate-buffered saline
PE phycoerythrin
r correlation coefficient
ROS reactive oxygen species
SCE sister chromatid exchange
SD standard deviation
SEM standard error of mean
SOD-1 cytoplasmic Cu2+/Zn2+ superoxide dismutase
SP senile plaque
SSB single strand break
TNF tumor necrosis factor
UVB ultraviolet B light
8-OH-dG 8-hydroxy-2 ’ -deoxyguanosine
8-OH-G 8-hydroxyguanosine
21q long arm of chromosome 21
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l. Intro ductio n
1.1. A lzheim er’s disease
A hundred years after the first description, Alzheimer’s disease (AD) is one of 
the most devastating age-related illnesses of the central nervous system (CNS) leading 
to dementia, and one of the most disabling and burdensome health conditions 
worldwide [35]. Today, according to the latest Delphi consensus study, 24-25 million 
people have dementia and this number will double every 20 years, assuming no changes 
in mortality and no effective prevention strategies or curative treatments. Of those with 
dementia, 60% live in developing countries, with this number rising to 71% by 2040. In 
Eastern Europe, an increase of 84% has been estimated in the number of people with 
dementia. Nowadays, the incidence of dementia in Hungary is 10% over the age of 
65 years, which means approximately 200 000 demented aging patients [126]. Taken 
together, due to the enhanced life expectancy of the general population, the aging 
community and thereby the dementia syndromes involved are becoming significant 
public health, social, economic and political problems all over the world. Therefore, 
intensive research is needed with the goals of elaborating efficient preventive, 
diagnostic and therapeutic possibilities via the identification of the risk factors, and an 
exact knowledge of the pathogenesis and clinical features of AD, one of the most 
common form of aging dementia (60-70%). The etiology of the disease is not yet 
known, and no really effective treatment is available.
To date, although the knowledge of the pathophysiological mechanisms 
implicated in the development of AD is far from complete, several parallel hypotheses 
have been proposed to explain its etiology, including the oldest cholinergic hypothesis, 
the oxidative stress (OS) hypothesis, the aberrant cell cycle hypothesis, the most recent 
“two-hit” (OS and cell cycle abnormalities) hypothesis, the cell death hypothesis, the 
“amyloid cascade” hypothesis, the inflammation hypothesis, the glutamate 
excitotoxicity hypothesis, the cholesterol hypothesis and the genetic hypotheses. The 
“amyloid cascade” hypothesis forms the most comprehensive interpretation, integrating 
all these theories, but it has some weaknesses, and ample evidence indicates that all the 
factors mentioned take part in the development of AD.
Three pathological hallmarks of AD are observed at autopsy: (1) extracellular 
senile (amyloid) plaques (SPs), (2) intracellular neurofibrillary tangles (NFTs) in large 
numbers in specific areas of the brain, and especially in the neocortex, hippocampus and 
other subcortical regions which are essential for the cognitive functions [125], and 
(3) vascular amyloid deposits in the cerebral blood vessels. Subsequent, additional 
characteristics of AD are deficits in multiple neurotransmitter (cholinergic, 
noradrenergic and serotonergic) signaling systems and synaptic loss, leading to the 
cardinal clinical symptoms: a progressive decline in cognition and memory, resulting in 
dementia associated with behavioral (affective) disturbances [117].
The classical SP in AD consists of a central core that is formed mostly from the 
deposition of beta-amyloid peptide (Ap), derived from cleavage of the amyloid 
precursor protein (APP) by p- and y-secretases, surrounded by a rim of dystrophic 
neurites and activated microglia and astrocytes. Neurotoxicity and neuronal death 
mediated by Ap have been shown to involve OS, perturbation of the intracellular 
calcium (Ca2+) homeostasis and the activation of apoptotic cell death pathways [22, 25, 
45, 76]. Thus, identification of molecular and cellular mechanisms that predispose 
neurons to apoptosis in AD may provide defined targets for new treatment strategies for 
the earlier diagnosis, prevention or amelioration of the course of the disease. The main 
component of the NFTs is the hyperphosphorylated protein tau, which assembles with 
neurofilaments into paired helical filaments. Several lines of evidence indicate that Ap 
aggregation is important in the etiology of AD, as is tau in its clinical 
manifestation [30]. Both SPs and NFTs play critical roles in the cytotoxic events 
causing the neuronal cell death that leads to dementia [23, 145].
The hereditary forms of AD generally have an earlier age of onset than that of 
the sporadic one. Mutations of the APP, presenilin-1 and -2 and apolipoprotein E 
(epsilon 4) genes seem to be the most important in causing these rare (1-5%), familial 
AD (FAD) autosomal dominant forms. However, there may be multiple genetic and 
environmental factors, e.g. OS, that affects the age of onset and disease progression.
1.2. D o w n ’s syndrom e
Down’s syndrome (DS) is one of the most common genetic abnormalities in 
livebom children (1 in 700-1000), leading to an early mental decline and premature 
aging. These patients often suffer from other aberrations, e.g. specific cardiac and 
gastrointestinal congenital malformations, various types of leukemias, cataracts and 
growth retardation [108]. Moreover, immune disorders such as celiac disease, a thyroid 
dysfunction and diabetes mellitus are also prevalent. Full trisomy of 
chromosome 21 (Chr 21) accounts for approximately 95% of the cases, and the 
remainder involve mosaicism or translocation to Chr 14 or 21. DS can affect many 
aspects of development, producing a wide and variable set of clinical features in a given 
person [106]. The excessive synthesis of multiple gene products derived from 
overexpression of the genes present on Chr 21 is thought to underlie both the 
dysmorphic features and the pathogenesis of the neurological, immunologic, endocrine 
and biochemical deviations that are characteristic of DS [103].
A link between the DS phenotype and an increased risk of the development of 
AD has now been firmly established [12]. A presenile dementia syndrome that is 
clinically, neuro- and histopathologically similar to AD [14, 47, 63] occurs in almost all 
those over the age of 40 years with DS. The prevalence of dementia among DS patients 
is 8% in the age range 35-49, 55% in the age range 50-59, and 75% above the age of 
60 years, but the AD neuropathology is present in all of the cases by the age of 40. This 
may indicate some common pathways and a close relationship between these two 
disorders.
1.3. T he role of oxidative stress in A lzheim er’s disease and  D o w n ’s
SYNDROME
One of the pipeline hypotheses, the “gene dosage effect” hypothesis of DS, holds 
that the dosage imbalance of a specific individual gene or a small group of genes is 
responsible for the specific individual DS traits [62, 106]. The presence of an extra copy 
of Chr 21, or rather the consecutive overexpression of the genes located on it, has been 
regarded as the central point for the development of the DS phenotype. Overexpression 
of the encoded proteins leads to overconsumption of their substrates and overproduction
of their metabolic end-products. The best-documented AD-associated gene products of 
this phenomenon are the APP and the cytoplasmic enzyme Cu2+/Zn2+ superoxide 
dismutase (SOD-1), both of which are responsible for the regulation of reactive oxygen 
species (ROS) homeostasis [113], which may be a fundamental factor in the 
development of OS, preceding the signature pathology by decades and leading to 
neuronal death and disease progression. However, not all proteins whose genes are 
encoded on this chromosome display overexpression, suggesting that the DS phenotype 
can not be explained simply by the “gene dosage effect” [15].
The “two-hit” hypothesis for AD recently proposed that either OS or alterations 
in the regulation of the cell cycle (mitotic signaling) can independently serve as 
initiators, but both processes are necessary and sufficient to propagate AD 
pathogenesis [148]. This model described in relation to AD may also have implications 
in DS and other neurodegenerative diseases. It has been suggested that susceptible 
neurons (under stress or bearing mutations) devote their compensatory potential to 
adjusting to current stimuli and thereby lose the capability of further adaptation needed 
to respond to other insults in the future. In other words, the first insult may leave the 
neurons very vulnerable to an additional insult. In light of this interpretation, it seems to 
be that OS alone is a necessary, but not sufficient event leading to AD.
1.3.1. The role of amyloid precursor protein in Alzheimer’s disease and Down’s
SYNDROME
The APP gene, mapped to Chr 2lq21.3-22.05, codes for a transmembrane 
protein expressed in both neurons and astrocytes. Recent years have seen significant 
advances in the understanding of Ap pathogenesis and the functional consequences of 
Ap accumulation, but there are still large gaps in our knowledge of the pathways 
involved in Ap degradation and clearance [48], Although the function of APP is not 
entirely clear, it is implicated in the neuroprotection against oxidative insults [52]. The 
close relationship between DS and AD may be attributed in part to an overdose of the 
APP gene and to the subsequent enhanced production of Ap. Mutations in the APP gene 
are connected with FAD, and it is hypothesized that the overexpression of APP causing
elevated A(3( 1-40/42) formation is the crucial event leading to the development of the 
AD pathology in DS [14].
According to the “amyloid cascade” hypothesis, the formation of Ap requires 
proteolytic cleavage of the large, type-1 integral membrane-spanning glycoprotein APP 
by secretases. APP can be processed into several different biologically active 
compounds, e.g. the soluble, secreted form (sAPP), derived from cleavage by a- and 
y-secretases, which has been shown to have neurotrophic activities, and the longer 
aggregating forms, of which AP(l-42) is the most toxic. A(3 itself could function as a 
neurotrophic factor for undifferentiated/differentiating neurons at low concentrations, 
but it could be neurotoxic to mature neurons at higher concentrations [143]. Ap begins 
to accumulate in DS in childhood (as young as 8 years) and its amount appears to rise 
progressively with increasing age [68]. In younger DS individuals (under 30 years), 
Ap accumulation is manifested by diffuse deposits that are not related with neuritic 
degeneration and consist of the toxic and less soluble peptide AP(l-42). Since SOD-1 
immunoreactivity has been reported to be absent from early diffuse plaques, it has been 
presumed that an elevated SOD-1 level may not be necessary in the initial pathologic 
events leading to SP formation [14]. Despite the fact of extensive extracellular Ap 
accumulation in the brain in both DS and AD, inconsistent associations have been 
published between Ap and dementia severity [24], pointing to the significance of some 
other (genetic or environmental) factors predisposing to dementia in DS. Between the 
ages of 35 and 45 years, the rate of AP-associated neuropathology accelerates [138], 
together with the NFTs (consisting mainly of intracellular deposits of 
microtubule-associated protein tau) and neuroinflammation [70]. In line with these 
findings, autopsy studies have demonstrated SPs and NFTs in the brains of all older DS 
patients, with some individuals showing a much earlier onset [68]. It has been suggested 
that an apoptotic mechanism may be involved in the process of ultimate neuronal death 
in DS [111].
Ap is neurotoxic directly by inducing OS, and indirectly by activating 
microglia [133, 134], The binding with the receptors of advanced glycation 
end-products (RAGEs/AGEs) increases the intracellular Ca2+ concentration, giving rise 
to apoptotic cell death [145]; this is related to an elevation in lipid peroxidation [13] and
can be stopped by catalase (CAT) and free radical scavengers. These results are in 
accordance with the notion that the alterations in the mitochondrial energy metabolism 
may be in the background of this process as a major endogenous source of ROS that 
contribute to neuronal apoptosis, leading to a chronic state of increased vulnerability to 
oxidative injury [10]. Energy depletion and OS can also induce amyloidogenic changes 
in APP processing [83], suggesting a potential link between a mitochondrial 
dysfunction, OS and A(3 production, as has been described in AD and DS brains [10, 
51]. Indeed, a reduced level of mitochondrial complex V (ATP synthase) P-chain 
protein has been noted in the DS cortex [61], indicating that the mitochondrial function 
impairment and OS are closely associated with DS. Despite the presence of enhanced 
neuronal apoptosis being refuted, unaltered levels of Fas, caspase-3, Bcl-2 and annexins 
(I, II, V and VI), proteins known to be associated with apoptotic cell death, have been 
reported in fetal DS brains [34].
In both AD and DS, alterations in APP metabolism have also been noted in the 
periphery, e.g. in the platelets [29], lymphocytes [98] and fibroblasts [131]. A systemic 
change in the APP metabolism was suggested by 2-3-fold enhanced plasma 
concentrations of both Ap(l-40) and Ap(l-42) in DS [130], which are in harmony with 
the findings that elevated APP contents have been revealed in both AD and DS 
lymphocytes [98], and an enhanced proportion of mRNA encoding for the three major 
APP transcripts (APP770+751/695) in DS fibroblasts [42].
1.3.2. The role of superoxide dismutase-1 in Alzheimer’s disease and Down’s
SYNDROME
Oxygen is necessary for life, but paradoxically, by-products of its metabolism 
produce ROS, including free radicals (superoxide (O2’“) and hydroxyl (OH‘) species) 
and other molecules, such as hydrogen peroxide (H2O2) and peroxynitrite, which have 
the ability to become highly toxic to cells [3]. The latter molecules can lead to the 
generation of free radicals through various chemical reactions. Thus, via the Fenton 
reaction, in the presence of reduced metal ions (e.g. ferrous or copper) as catalysts, H2O2 
can be converted to OH‘. Peroxynitrite, formed by the reaction of nitric oxide with O2* , 
is a highly reactive molecule that also breaks down to form OH’. Together, ROS can
interact with cellular components such as proteins, lipids and DNA [128], and 
ultimately cause cell death.
OS is defined as the lack of balance between the generation and removal of 
ROS, which may play a significant part in the pathogenesis of both DS and AD [9, 44, 
60, 114]. SOD-1 is thought to have a major role in the first line of antioxidant defense 
by catalyzing the transformation of 0 2‘” to molecular oxygen (0 2) and H20 2, which can 
be converted by CAT and glutathione peroxidase (GPX) to water. The triplication of 
Chr 21, on which the SOD-1 gene is localized (mapping in 21 q22.1), leads to an 
imbalance in the ratio of SOD-1 to CAT and GPX, resulting in the accumulation of 
H20 2.
A recent observation that SOD-1 forms proteinaceous aggregates that are related 
to SPs in AD brains for the first time implicated the involvement of oxidative damage to 
SOD-1 in the AD pathogenesis [16], confirming the close connection between DS and 
AD. An increased SOD-1 activity in the cerebrospinal fluid (CSF) with aging has been 
reported in AD, suggesting a possible compensatory process, secondary to the increased 
OS, with time [96]. The same adaptive, OS-activated responses were hypothesized in 
both AD and DS neurons [85, 147], which reduce the oxidative injuries by inducing 
apoptosis or protective mechanisms and ensure that the neurons do not rapidly succumb 
to OS. It has been suggested that A0 deposition and tau hyperphosphorylation function 
as compensatory responses and downstream adaptations.
Not only the CNS, but all DS tissues display an altered SOD-l/GPX activity 
ratio [27]. SOD-1 is found at levels approximately 50% higher than normal in a variety 
of DS cells and tissues, including erythrocytes, neutrophils, B and T lymphocytes and 
fibroblasts [88, 101, 118], which may affect the gene expression by altering the binding 
and/or availability of transcription factors, e.g. nuclear factor kappa B (NF-kB) [27] and 
the activator protein (AP)-l [1], to DNA. This is in harmony with the recent observation 
on AD lymphoblasts that serum addition induced an increase in NF-KB-DNA-binding 
activity [28]. NF-kB opposes apoptosis through the induction of antiapoptotic Bcl-2 
family members and some inhibitors of apoptosis proteins. Indeed, inhibition of NF-kB 
activation produces a corresponding increase in apoptosis, indicating that the balance of 
cell viability versus cell death is maintained by the degree of NF-kB activation.
1.3.3. Apoptosis in Alzheimer’s disease and Down’s syndrome
Cell death can occur by either of two specific cellular mechanisms, necrosis or 
apoptosis, with different characteristic morphological and biochemical features. The 
former (“accidental” cell death) is a pathological process which appears when cells are 
exposed to a serious physical or chemical insult, e.g. hypothermia and hypoxia, and 
results in a significant inflammatory response. In contrast, apoptosis, also known as 
“programmed” cell death, is a complex, conserved and tightly regulated physiological 
event that takes place continuously throughout life in the whole organism, and may 
occur in different varieties, e.g. “paratosis” or “abortosis” [136]. It helps to eliminate 
unnecessary and aged or damaged cells and maintains tissue homeostasis [30]. Recent 
accumulating evidence strongly suggests that apoptosis may additionally contribute to 
neuronal death in a variety of neurodegenerative disorders [75]. During apoptosis, the 
cell body shrinks, the plasma membrane blebs and the nuclear DNA (nDNA) condenses 
and fragments, while the organelle integrity is preserved until late stages of the process. 
Exposure of acidic phospholipids on the cell membrane is a signal for the ultimate 
recognition and phagocytotic uptake of cells undergoing apoptosis, ensuring that no 
inflammatory response is elicited in the neighboring tissue. In vitro, the apoptotic bodies 
and remaining cell fragments swell and finally lyse; this terminal phase has been termed 
“secondary necrosis”.
Several apoptosis-inducing factors have been identified, e.g. OS, DNA damage, 
a disturbance in Ca2+ homeostasis, ceramides, the withdrawal of growth factors and 
infections, but the exact mechanism of apoptosis, i.e. the cascade of events starting from 
the detection of the signal at the cell surface to the events that occur in the nucleus, has 
not yet been clarified [110]. The occurrence of apoptosis involves relatively few 
pathways that converge on activation of the caspase (cysteine aspartate-specific 
protease) cascade [38]. Generally, caspases are found in relatively large amounts as 
inactive precursors/proenzymes (procaspases) within the cytoplasm and they undergo 
processing to form activated heterotetramers upon proteolysis. The central players in the 
apoptotic program are the upstream initiator caspases (8, 9 and 10); these activate other 
caspases, called effector caspases (3, 6 and 7), which are important regulators of 
postmitotic homeostasis. The latter, downstream, executioner caspases are responsible 
for the majority of the intracellular caspase-induced cleavages that result in cell death.
Two principal pathways are well known with respect to the activation of 
caspases: the cell surface death receptor (members of the tumor necrosis factor (TNF) 
receptor superfamily, e.g. TNF-a- and Fas-receptor) pathway and the mitochondrial 
pathway. In the former, the activation of caspase-8 is the critical event that transmits the 
death signal, and in the latter, caspase activation is triggered by the formation of an 
apoptotic protease-activating factor-1 (Apaf-l)/cytochrome c complex that is fully 
functional in recruiting and activating procaspase-9, and creating the “apoptosome”
(Fig- !)•
On the one hand, the initiator caspase-8 directly activates caspase-3, and on the 
other hand, it cleaves one of the proapoptotic members (Bax, Bad and Bcl-xs) of the 
Bcl-2 family, Bid, giving rise to the promotion of apoptosis: Bid translocates to the 
mitochondrial membrane, where it interacts with the one of the antiapoptotic members 
of this protein family, Bcl-2. These events result in the formation of a mitochondrial 
transition pore and the release of cytochrome c into the cytoplasm [57]. Subsequently, 
caspase-9 cleaves and activates downstream caspase-3, finally resulting in the 
occurrence of apoptosis.
The proto-oncogene Bcl-2 protects cells from the apoptotic consequences of 
oxidative damage: its overexpression blocks the lipid peroxidation that accompanies 
apoptotic cell death. The balance of pro- and antiapototic members of the Bcl-2 protein 
family determines whether apoptosis is promoted or prevented.
Ultraviolet (UV) radiation (wavelength band: 100-400 nm), and in particular 
UVB with a wavelength range in the interval 290-320 nm, is one of the most important 
environmental factors affecting humans [65]. A crucial event following exposure of the 
skin to UVB light is the formation of sunburn cells within the epidermis; these are in 
fact severely UVB-damaged cells which bear the risk of becoming malignant and which 
therefore undergo apoptosis in favor of the surrounding tissue. Although the majority of 
studies were performed with epidermal cell lines and primary keratinocytes, evidence 
exists that this concept also holds true for other cell types. UVB-mediated apoptosis is a 
highly complex process involved in a variety of signaling pathways, including DNA 
damage, cell death receptor activation and the generation of ROS. To exert its biological 
influences, UV radiation has to be absorbed by a cellular chromophore that transduces 
the energy into a biochemical signal. In this respect, genomic DNA has been regarded as
being the main target for UVB since the absorption maximum matches the action 
spectrum of biological UVB effects (the DNA absorption peak is at 260 nm). The DNA 
damage seems to predominate (see Section 1.3.4.2), but UVB can also influence 
molecular targets, via either a direct and ligand-independent activation of 
membrane-bound cell death receptors or the mitochondrial apoptotic pathway. UVB is 
known to be a potent inducer of ROS that initiate cellular damage and apoptosis: 
changes in the structure of the inner mitochondrial membrane result in a loss of the 
membrane potential and subsequent cytochrome c and ROS release into the 
cytoplasm [65].
Apoptosis is a potentially important event for the initiation of both AD and DS 
and progression of the neuronal loss [4, 7, 56], implicating a disturbed Ca2+ 
homeostasis, a mitochondrial dysfunction and a caspase activation in OS. Additionally, 
ample evidence of augmented apoptosis has been reported not only in the brain, but also 
in the periphery, e.g. in the lymphocytes [33, 112], cells which at the same time 
represent the main compartment of the immune system. A higher concentration of 
8-hydroxy-2’-deoxyguanosine (8-OH-dG), a marker of oxidative damage to the DNA, 
has been demonstrated in AD lymphocytes [79], reflecting cell injury. Mitogen-induced 
cultured T cells from AD patients have revealed that elevated levels of caspase 
activation [123] and intracellular Ca2+ are prerequisites for apoptosis [122], supporting 
the theory of the hypersensitivity of these cells to apoptotic stimuli. Furthermore, Ap, 
the major neurotoxic protein component of SPs, is able to promote apoptotic death in 
lymphocytes in vitro via an OS mechanism [132]. In DS, an altered free radical 
metabolism and an impaired mitochondrial function are linked to neuronal 
degeneration [4, 11] that may be associated with both mental retardation and AD 
pathology in these patients. In addition to the overexpression of the above-mentioned 
APP and SOD-1 genes located on Chr 21, the Ets-2 family of transcription factors is 
also involved in multiple cellular processes, including the activation of signaling 
cascades [49]. Elevated levels of Ets-2 predispose to apoptosis via a p53-dependent 
mitochondrial pathway and an activation of caspase-3 in fibroblasts overexpressing 
Ets-2, in primary neuronal cultures from ETS-2 transgenic mice and in both DS and AD 
cortical neurons, supporting the involvement of a dysfunction of the mitochondria and
increased apoptosis in DS and AD neuropathology [49, 109,140]. The tumor suppressor 
gene p53 has a critical role in the regulation of the cell cycle: it is required for Gj/S 
arrest, allowing the cell to accomplish DNA repair prior to DNA synthesis, thereby 
reducing the DNA mutation rate.
Cell surface death receptor pathway 
Mediators/modulators Receptor-associated death domain
1
Mitochondrial pathway 
Cytochrome c, Apaf-1, 
Bcl-2, Bax
Initiator caspases 
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Apoptosis
Fig. 1. Molecules implicated in the two main signaling pathways of apoptosis.
1.3.4. Oxidative stress-induced DNA damage and repair in Alzheimer’s disease 
and Down’s syndrome
1.3.4.1. DNA damage in Alzheimer’s disease and Down’s syndrome
ROS-mediated oxidative injury can result in DNA modifications, including base 
alterations, single (SSBs) and double strand breaks (DSBs), sister chromatid exchanges 
(SCEs) and DNA-protein crosslinks [119]. The contributions of free radical-mediated 
DNA cleavage, ongoing or incomplete DNA repair processes or endonuclease cleavage 
as part of an apoptotic cascade to the generation of DNA strand breaks are 
unknown [26], but recent evidence suggests that they may have fundamental and 
complex roles in both AD and DS progression.
DNA strand breaks can be detected by the alkaline elution assay at the tissue 
level, or by terminal deoxynucleotidyl transferase-mediated in situ end-labeling or 
comet assay at a single cell level (see Section 2.2.2.2). SCE, the exchange of 
homologous stretches of DNA between sister chromatids, normally occurs in cells
during mitosis or cell division, but when the DNA is damaged by genotoxic agents, the 
rate of SCE increases.
Mainly OH' plays a major role in the formation of oxidative DNA damage. Since 
the copper ion (see Section 1: Fenton reaction) participates in the attachment of DNA to 
the nuclear matrix, it is likely that OH’ is formed in close proximity to the DNA 
target [18], generating strand breaks with various sugar modifications and simple abasic 
sites. Free radicals can damage all four DNA bases, and therefore methods have been 
developed for the detection of all these modified bases. One of the best-characterized, 
8-OH-dG, is the most predominant marker of in vivo oxidative DNA damage resulting 
from OH' attack on deoxyguanosine.
Indeed, a higher incidence of SSBs, DSBs and alkali-labile DNA lesions has 
been detected in the AD cerebral cortex [2, 89, 120]. On the other hand, both increased 
and unaltered 8-OH-dG levels have been described in AD brain nucleus samples [39, 
116, 127]. In contrast, there was not found to be a significant elevation in the 8-OH-dG 
content of postmortem aged DS brain tissues [116], questioning the involvement of OS 
in the DNA damage leading to neuronal apoptosis in DS. A complex study has reported 
augmented degrees of some other (8-OH-adenine, 8-OH-guanine and thymine glycol), 
but not all oxidized bases in the AD cerebral cortex [73]. The amounts of multiple 
oxidized bases of both nDNA and mitochondrial DNA (mtDNA) were greater in the 
frontal, parietal and temporal lobes in AD as compared with the controls [137]; and, as 
expected, DNA from the temporal lobe displayed the most oxidative damage, whereas 
the cerebellum was only slightly affected, since the cerebellum is poor in Ap deposition. 
The 8-hydroxyguanosine (8-OH-G) (the main oxidation product of RNA) 
immunoreactivity was demonstrated to be enhanced in young DS patients, whereas the 
Ap burden was elevated only after the age of 30 years; the increased level of oxidative 
damage therefore appears prior to the onset of Ap deposition in DS brains [93]. This 
observation is in harmony with the presumption of the presence of in vivo OS and 
suggests that chronic oxidative injury constitutes a risk factor for subsequent 
neurodegeneration in aged DS patients [11]. Likewise, a systematic examination of the 
spatiotemporal link between the extents of 8-OH-dG, 8-OH-G and the hallmark AD 
lesions at early AD stages indicated that markers of OS are present in those susceptible
neurons without NFTs [94], confirming the primacy of OS. On the other hand, neurons 
containing NFTs showed a decrease in relative 8-OH-G level as compared with neurons 
free of NFTs, and the same relationship was noted between 8-OH-G immunoreactivity 
and A(3 deposition, similarly to the findings in DS [93]. These observations also point to 
the oxidative damage being an early event in the pathogenesis of both AD and DS, and 
to the fact that it decreases with disease progression and increased histopathology, 
suggesting compensatory intracellular mechanisms that reduce OS [92]. In both AD and 
DS brains, this pattern of oxidation to RNA coincided with that of a protein oxidation 
marker (3-nitrotyrosine) which may reflect global levels of OS.
In the single published comet assay study on lymphocytes from newborns with 
DS, a significantly elevated number of strand breaks was reported [74]. SCE studies on 
both AD and DS lymphocytes and fibroblasts have exhibited an increased or unchanged 
frequency following different types of exposure [40, 41, 80, 129, 141]. Likewise, both 
enhanced and unaltered levels have been described as concerns SSBs in resting AD 
lymphocytes and leukocytes [82, 87]. An elevated level of 8-OH-dG in the intact DNA 
and a decreased concentration of its free repair product were demonstrated in the 
CSF [71] and lymphocytes [78, 79] of AD individuals. In line with these observations, 
enhanced amounts of oxidized purines were described in AD lymphocytes [59, 87] and 
leukocytes [82], supporting the existence of a heightened OS in vivo. The higher level of 
urine 8-OH-dG found in DS [46] may also be in agreement with the observed premature 
aging and the enhanced incidence of dysfunctions (e.g. infections, cancer and cataracts) 
and early AD-like changes in DS.
1.3.4.2. The repair of oxidative stress-induced DNA damage
Three fundamental cellular responses to DNA damage have been identified in 
living cells: reversal, excision and tolerance. The latter practically does not involve a 
DNA repair mechanism, because it does not include the removal of the damage even it 
often leads to permanent mutations. The reversal of damage in DNA is the most direct 
mode of DNA repair, with a number of advantages, e.g. only a single gene product is 
required, it is relatively error-free because of the high degree of specificity, and it is 
more rapid than multistep biochemical pathways such as excision repair. However, the
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types of DNA damage that are repaired by direct reversal are limited. The most general 
DNA repair mode observed in nature is one in which damaged, mispaired or 
inappropriate bases are excised from the genome and replaced by the normal nucleotide 
sequence and chemistry, including base excision repair (BER) (Fig. 2), nucleotide 
excision repair (NER) and mismatch repair.
The DNA damage induced by OS may be repaired by a variety of pathways, but 
particularly by BER (Fig. 2) [72]. Failure to repair oxidatively modified bases in DNA 
may lead to the accumulation of damage and result in a decay in normal cell functions, 
which could contribute to the aging process and age-related disorders [72]. Although the 
BER pathway is the main repair mechanism for the handling of oxidative DNA damage, 
the finding that the expressions of NER enzymes (DNA helicases) and their mRNA 
levels were higher in the brains of both DS and AD individuals [50] may indicate 
ongoing oxidative DNA damage. Ionizing radiation, which is considered to cause 
chromosomal instability, did not affect the DNA synthesis in DS fibroblasts [6], whereas 
the normal repair of SSBs and DSBs was seen in both fibroblasts [121] and 
lymphocytes [67]. Moreover, DS lymphocytes displayed a lower DNA repair efficiency 
and an accelerated decline in DNA repair capacity with age that is one of the probable 
reasons for the premature aging [104].
The mtDNA is 10 times more vulnerable to oxidative damage in vivo as 
compared with nDNA, and an enhanced ROS concentration is known to give rise to 
damage in it. Indeed, in agreement with these observations, DS fibroblasts displayed a 
reduction in their mtDNA repair ability [32], and AD and other age-related 
neurodegenerative disorders have been demonstrated to be associated with mutations in 
mtDNA [51].
Some researchers have detected decreased UV light-induced DNA repair in DS 
fibroblasts [105], leukocytes [66] and lymphocytes [104], while others have not [144]. 
UVB introduces preferably two types of DNA damage, cyclobutane pyrimidine dimers 
and 6-4 photoproducts, these latter lesions being removed by NER. Upon UVB 
irradiation of the cells, gene p53 was found to be upregulated proportionally to the 
amount of cyclobutane pyrimidine dimers introduced into the genomic DNA [65]. The 
cells have evolved complex signaling pathways to arrest the progression of the cell cycle
in the presence of DNA damage, providing increased time for repair (and tolerance) 
mechanisms to operate, resulting in a reduced apoptotic rate [37], Finally, when the 
burden of genomic insult is too large to be effectively met by the various responses, the 
cells are able to initiate apoptosis, eliminating themselves from a population that 
otherwise might suffer serious pathological consequences. Thus, the nDNA damage 
plays a crucial role in the mediation of UVB-induced apoptosis; when the DNA repair 
enzymes are inadequate to fix the damage, apoptosis is the most effective defense 
mechanism against DNA damage and mutation.
Step 2: AP endonucleases 
or AP lyases produce 
(single) strand breaks at 
the 5’ or 3’ end
Step 4\ DNA polymerases 
and DNA ligases fill the 
gap, restoring the strand 
continuity
Step l : DNA 
glycosylases remove 
the damaged base
Step 3: DNA
deoxyribose
phosphodiesterases
remove the
remaining
deoxyribose
phosphate residue
3’
Fig. 2. Schematic representation of BER, correcting most of the oxidative DNA damage. For 
simplicity, only the relevant DNA strand is shown.
AP, abasic site; B, base (adenine, thymine, cytosine or guanine); dR, deoxyribose; P, 
phosphate
1.4. AIMS
I. 1. To determine whether UVB irradiation can induce apoptosis in
T lymphocytes from AD and CNT individuals.
2. To compare the UVB irradiation-induced apoptotic responses of the 
T lymphocytes from AD and CNT subjects.
3. To determine whether the extent of cell death in the T lymphocytes of AD 
and CNT individuals depends on the UVB doses applied.
II. 1. To compare the extents of basal oxidative damage of the nDNA of the 
lymphocytes from DS and CNT subjects and to determine whether this parameter 
depends on the age (children and adults).
2. To compare the vulnerabilities of DS and CNT lymphocytes to in vitro OS 
induction at the DNA level and to determine whether this parameter depends on the age.
3. To compare the repair capacities of the induced oxidative DNA damage in 
the lymphocytes of DS and CNT individuals and to determine whether this parameter 
depends on the age.
2. Subjects and  M ethods
2.1. Subjects
2.1.1. Alzheimer’s disease patients and their corresponding controls
Thirty-four subjects participated in this project. Twenty-two patients with mild 
AD were selected according to the DSM-IV (Diagnostic and Statistical Manual of 
Mental Disorders 4th edition) and the NINCDS-ADRDA (National Institute of 
Neurological and Communicative Disorders and Stroke, and Alzheimer’s Disease and 
Related Disorders Association) criteria [77]. All of them were probable, late-onset, 
sporadic cases. Twelve healthy control (CNT) individuals of similar age, but without 
dementia, were selected from among the spouses of patients visiting the local Memory 
Clinic. The age, gender and Mini-Mental State Examination (MMSE) scores [36, 54] of 
the AD and the CNT subjects are presented in Table 1.
None of the subjects were taking any medication known to interact with the 
lymphocyte functions or the apoptotic mechanisms. None of them were alcohol or 
nicotine users. Their routine blood laboratory parameters were within the normal ranges. 
There was no indication of any kind of immune disorder, severe infection or malignancy 
in their past history or in their present physical examination.
Table 1. Clinical data on the AD patients and their corresponding CNT probands 
(mean ± standard deviation (SD))
CNT 
(n—12)
AD
(n=22)
Age (years) 70 ±7.1 75 ± 7.2
Age range (years) 63-86 61-82
Gender (male/female) 1/11 4/18
Age of dementia (AD) onset (years) - 69 ± 2.3
MMSE score (maximum 30 points) 29 ± 1.2 21+2.0*
*p=0.000 (pO.OOOl)
2.1.2. Down’ syndrome patients and their corresponding controls
Fifty subjects participated in this study. The DS group consisted of 25 patients 
living either in communities or in institutions. They were divided into two main age 
categories: children (<18 years) and adults (>18 years) (Table 2). The clinical diagnosis 
of DS was confirmed by chromosome analysis: all the DS subjects demonstrated 
trisomy of Chr 21. Seven DS individuals (3 children, 4 adults) had chronic medical 
problems, e.g. heart defects, diabetes mellitus, renal insufficiency or gastrointestinal 
disorders. Patients with other diseases that were current or in their history or who had 
participated in the last 6 months in antilymphocyte, anti-inflammatory or antioxidant 
medication known to interfere with the lymphocyte number and/or function were 
excluded. The routine blood laboratory parameters, differential and total leukocyte 
counts and urinalysis results were within the normal ranges. Six DS subjects were taking 
low doses of psychotropic medication, i.e. carbamazepine, clonazepam, diazepam or 
sodium valproate, but there were no differences between these treated and the untreated 
patients as concerns the parameters examined in this work.
The CNT group comprised 25 gender- and age-matched healthy individuals. 
Their mean age, age range and gender distribution were comparable to those in the DS 
group (14 males, 11 females (p=0.78); age: 23 ± 12.1 (mean + SD) years (p=0.96); age 
range: 3-57 years). The CNT subjects were also divided into two age categories: <18 
and >18 years (Table 2). They had neither active medical problems nor any personal or 
family history of neurological or psychiatric disorders, alcohol or drug abuse, severe 
infection or malignancy, as determined via clinical interviews and physical 
examinations. None of the adult CNT individuals met the clinical criteria for dementia 
syndrome or mild cognitive impairment, and they were not taking any preventive 
medication (antioxidant or vitamin treatment). All of the CNT subjects yielded normal 
results as regards the routine blood chemistry, differential and total leukocyte counts and 
urinalyses.
Table 2. Clinical data on the DS patients and their corresponding CNT probands overall 
and in the two age categories (mean ± SD)
Total
(n=25)
CNT
Children
(n=7)
Adults
(n~18)
Total
(n=25)
DS
Children
(n=7)
Adults 
(n=l 8)
Age (years) 23 ± 12.1 8 ±4.2 29 ± 8.6 23 ± 12.8 8 + 3.6 29 ± 10.0
Age range (years) 3-57 3-15 21-57 4-58 4-14 18-58
Gender (male/female) 14/11 3/4 11/7 13/12 3/4 10/8
2.2. M ethods applied
2.2.1. Measurement of apoptotic damage in Alzheimer’s lymphocytes
2.2.1.1. Isolation and in vitro ultraviolet B irradiation of lymphocytes
Venous blood samples were collected between 9 and 11 a.m. Peripheral blood 
mononuclear cells (PBMCs: granulocytes, monocytes and lymphocytes) were prepared 
by density gradient centrifugation from EDTA (ethylenediaminetetraacetic 
acid)-anticoagulated blood. The freshly drawn, whole blood was diluted 1:1 in 
phosphate-buffered saline (PBS). The mononuclear cell interface was collected over 
Ficoll (type 400) (Sigma, Germany) (l:l=Ficoll solution : blood in PBS) after 
centrifugation at 400 g for 30 min at room temperature. The PBMCs were washed three 
times in PBS (300 g, 10 min). The cells in uncovered 24-well tissue culture plates 
(Nunclon, Denmark) were irradiated at a final concentration of 106 cells/well in PBS at 
308 nm with a XeCl (xenon chloride) UVB-laser apparatus (Photomedex Incorporation, 
USA). The exposure doses applied were 100,200 or 300 mJ/cm2, as previously reported 
[53, 91]. The frequency of the impulses was 200 Hz and their energy was 3 mJ, with a 
pulse width of 30 nanoseconds. The PBMCs were washed once (300 g, 10 min) after the 
irradiation and resuspended in a complete RPMI 1640 medium (Gibco, Scotland) 
supplemented with 10% AB-positive heat-inactivated human serum (Sigma, Germany), 
2 mM L-glutamine and antibiotics (0.1 mg/ml streptomycin and 100 IU/ml penicillin) 
(Gibco, Scotland). The cells were cultured for 20 h at 37 °C in the presence of 5% CO2.
2.2.1.2. Flow cytometry measurements
The PBMCs were stained with a 10-pl anti-human CD3-FITC (fluorescein 
isothiocyanate) monoclonal antibody (mAh) (Dako, Denmark) cell suspension (106 cells 
in 100 pi of PBS) for 30 min at 4 °C. Samples were then washed twice with PBS 
containing 2% bovine serum albumin. The cells were fixed in 2% paraformaldehyde for 
30 min at room temperature, and permeabilized for 15 min on ice in 0.01% saponin in 
PBS supplemented with 1% fetal bovine serum and 0.02% sodium azide. Later, 20 pi of 
Apo2.7-PE (phycoerythrin) mAb (Immunotech, France) and 80 pi of PBS were added, 
and the liquid was left to stand for 15 min at room temperature. Apo2.7-PE mAb binds 
to a 38 kDa mitochondrial membrane protein which appears on cells undergoing 
apoptosis [146]. To exclude false-positive reactions, the CNT samples were stained with 
isotype-matched anti-human IgG(-PE mAb. Finally, the cells were resuspended in 
250 pi of PBS and analyzed by flow cytometry. The percentage of Apo2.7-PE- and at 
the same time CD3-FITC-positive PBMCs, in other words apoptotic T cells, as 
compared with the total number of T lymphocytes was acquired on a FACStar Plus 
(Becton Dickinson, USA) flow cytometer, using CellQuest software (Becton Dickinson, 
USA).
2.2.2. Measurement of oxidative DNA damage in Down’s lymphocytes
2.2.2.1. Isolation and in vitro oxidative stress induction of lymphocytes
EDTA-anticoagulated venous blood samples were collected between 7 and 
9 a.m. At the same time, qualitative blood tests were performed in order to exclude 
acute diseases. Lymphocytes were immediately prepared from 1 ml of freshly drawn, 
whole blood with Histopaque 1077 (Sigma, Germany). The interface was collected after 
centrifugation at 200 g for 15 min at room temperature. The cells were then washed 
twice in PBS (200 g, 5 min). The order of the yields was 106cells/ml blood.
One-third of the separated lymphocytes remained untreated, and were used to 
detect the basal, spontaneous DNA damage levels. The remainder were treated with 
100 pM H2O2 in PBS for 5 min on ice in order to induce oxidative DNA damage, which 
can reflect the antioxidant status of the cells [17]. The lymphocytes were washed three 
times in PBS, and half of the treated cells were then resuspended in 1 ml of RPMI 1640
medium (Gibco, Scotland) supplemented with 2 mM L-glutamine and antibiotics 
(0.1 mg/ml streptomycin and 100 IU/ml penicillin) (Gibco, Scotland) and incubated at 
37 °C for 1 h in the presence of 5% C02, as previously described [19, 87], to allow the 
process of DNA repair. A 1-h time interval proved appropriate for the correcting 
processes to take place in both DS and CNT samples during our previous optimization 
of the method, and there was no sign of better removal during incubation for 2, 3 or 4 h, 
as found in previous publications [19, 21]. It did not appear advisable to choose a too 
long repair period, because the DNA repair of isolated lymphocytes is not highly 
efficient [20], and atmospheric oxygen could induce oxidative damage, possibly leading 
to artifacts [18].
2.2.2.2. Comet assay
The comet assay, also known as single-cell gel electrophoresis, is suitable for the 
quantification of genomic damage at the individual cell level and for the specific 
detection of DNA SSBs, alkali-labile sites, DNA-DNA or DNA-protein cross-linking, 
and DNA adducts and SSBs associated with incomplete excision repair sites [81]. 
Damage to nucleic acids caused by ROS includes base modifications, SSBs and DSBs if 
the SSBs are in close proximity [26]. The combination of the alkaline comet assay with 
the digestion of DNA by two lesion-specific (excision repair) endonucleases provides 
information about specific oxidative damage involving endonuclease III (EndoIII) [531] 
and formamidopyrimidine DNA-glycosylase (Fpg) [8]. These enzymes recognize and 
cut oxidized pyrimidines and purines, respectively, and convert these damaged sites into 
SSBs, producing fragments which migrate toward the anode during electrophoresis, 
forming the tail of the comet in the assay.
The modified alkaline comet assay [20, 87] was carried out according to the 
following protocol. Two sets of microscope slides were prepared for each experimental 
point and the average values were used for statistical analysis. Slides were spread with 
160 pi of 1% normal-melting agarose (Sigma, Germany) in PBS, covered with a 
coverslip, and left at 4 °C to solidify. Centrifuged lymphocytes were suspended with 
70 pi of 0.75% low-melting agarose (Sigma, Germany) in PBS at 37 °C, rapidly 
dropped onto the first agarose layer, covered with a coverslip, and left at 4 °C for 5 min
to solidify. After removal of the coverslips, the slides were incubated for 1 h in freshly 
prepared, cold lysis buffer (2.5MNaCl, 0.1 M Na2EDTA, 10 mM Tris, pH 10, 
1% Triton X-100 added fresh) to remove cellular proteins. This treatment leaves 
residual nuclei embedded in the gel and makes the DNA susceptible to the following 
lesion-specific endonuclease treatment.
After lysis, the slides were washed three times for 5 min with enzyme buffer 
(40 mM HEPES, 0.1 M KC1, 0.5 mM EDTA, 0.2 mg/ml bovine serum albumin, pH 8) 
at 4 °C for 5 min. 50 pi of enzyme buffer (used as control) or buffer containing 
EndoIII (dilution: 1:10 000) (Biolabs, New England) or Fpg (dilution: 1:3 000) (Biolabs, 
New England) was dropped onto the slides, which were next covered with a coverslip. 
The slides were then placed into a moist box and incubated at 37 °C for 45 min.
After incubation, the coverslips were removed and the slides were placed into an 
ice-cooled horizontal gel electrophoresis tank filled with freshly made 4 °C alkaline 
buffer (0.3 M NaOH, 1 mM EDTA, pH 13) and left in this solution for 20 min to allow 
DNA unwinding. The DNA fragments were then separated by electrophoresis for 
20 min at 25 V and 300 mA. After electrophoresis, the slides were flooded with three 
changes of neutralization buffer (0.4 M Tris, pH 7.5) at 4 °C for 5 min, and drained 
before staining with ethidium bromide (20 pg/ml).
Finally, the slides (each containing a minimum of 104 cells) were viewed under 
coverslips, using a fluorescence microscope (Axioskop 2 MOT, Zeiss) equipped with a 
digital camera (Axiocam, Zeiss). Observations were performed at a magnification of 
400x (Axiovision 3.1 photo program (Zeiss)). 100 randomly selected cells from each 
replicate slide were evaluated by using Komet 5.0 video image analysis software 
(Kinetic Imaging Ltd., Liverpool, UK). Results are reported as the percentage of DNA 
in the comet tail for each cell (“tail DNA %”), which is indicative of the extent of DNA 
damage, expressed as the mean of the sum of the “tail DNA %” ± SEM (standard error 
of mean). The comet assay has long been known to give high SD values (evidence of the 
high interindividual variation) [64, 74, 139]. Accordingly, all our data are expressed as 
means ± SEM.
Strand breaks generated by the enzymes applied are added to the SSBs (and 
alkali-labile sites), and thus the values obtained for enzyme-treated slides include the
amounts of the given oxidized base together with the SSBs. Since unrepaired, residual 
damage is detectable only with the comet assay, the amount of repaired damage can be 
calculated as the difference from the stress-induced value (repaired 
damage = stress-induced damage -  residual damage).
2.3. Statistical  analysis
In the apoptosis study, SPSS 9.0 for Windows was used for statistical analysis. 
Two-way ANOVA (analysis of variance) was applied to determine the differences 
between the AD and CNT groups and the data relating to the various UVB doses. The 
relationships between the age, the severity of dementia and the degree of apoptosis were 
determined via the Pearson correlation.
Statistica for Windows 6.1 was used for statistical analysis in the oxidative DNA 
damage investigation. First, a three-way ANOVA was used, but since the effect of 
gender and the three-way interaction were not statistically significant, a two-way 
ANOVA was applied to determine the differences between groups (DS or CNT) and the 
dependence on age (i.e. the age categories of children and adults). The non-significant 
interactions of the groups and the age categories (Table 4) indicated that the extent of 
given DNA damage did not depend on the age categories. This means that the 
differences between the DS and CNT groups were independent of age. In these cases, 
therefore, further pairwise comparisons according to age categories were performed only 
for completeness (Tables 5A and B). Additionally, some significant differences 
concerning the overall groups could no longer be detected because of the subsequent 
small size of the sample. When the interactions were significant (or close to the level of 
significance) (Table 4), the differences between the DS and CNT groups were tested 
separately in children (Table 5A) and adults (Table 5B) by performing pairwise 
comparisons on estimated marginal means with the LSD method. The relationships 
between age and the degree of DNA damage were determined via the Pearson 
correlation. A level p<0.05 was considered to be statistically significant.
3. Results
3.1. A poptosis in A lzheim er’s lym phocytes
Lymphocytes from CNT and AD subjects which were cultured for 20 h without 
UVB irradiation underwent apoptosis to only a minimal degree (less than 4%) (Table 3). 
This spontaneous apoptotic death was considered to be the baseline. In this 
non-irradiated state, no significant difference was observed between the two groups 
(p=0.84) as regards cell death.
In both groups, the rate of UVB-induced cell death was enhanced to an extent 
depending on the intensity of the exposure (Table 3). However, the AD lymphocytes 
underwent apoptosis to a significantly (pO.OOOl) lesser degree than did the CNT 
lymphocytes at each dose. Flow cytometric histograms representing results on one AD 
and one CNT proband are shown in Fig. 3. Within both groups, there were significant 
differences between the apoptotic values at the UVB intensities of 100 and 200 mJ/cm2 
(Pcnt=0.001, /?a d= 0.0001), but no differences were found between the 200 and 
300 mJ/cm2 doses (/?cnt=0.978, /?Ad=0.158). The differences in the apoptotic values 
between the two groups were dependent on the dose applied (p interaction< 0 .0 0 0 1 ) .
There was no significant correlation between the degree of apoptosis and the age 
of the subjects (correlation coefficient (r)=0.059 [p=0.569]). A significant, but weak 
negative relationship was found between the apoptotic values and the severity of 
dementia (r of MMSE scores=0.202 [p<0.05]). There was an approximately 22% 
inter-experimental variation in the apoptotic values (data not shown).
Table 3. Degree of UVB-induced apoptosis in AD patients and their corresponding 
CNT probands (mean ± SD)
Dose of irradiation 
(mJ/cm2)
CNT
(n=12)
Apoptosis (% of T cells)
AD
(n=22)
Apoptosis (% of T cells)
Significance 
(CNT versus AD) 
p value
0 3.14 ± 1.70 3.81 ± 1.82 0.840
100 55.52 ± 9.42 35.04 ±8.68 0.0001
200 69.40 ± 6.87 51.76 ±9.48 0.0001
300 69.51 ±9.23 55.81 ±9.76 0.0001
0 mJ/cm2 100 mJ/cm2 200 mJ/cm2 300 mJ/cm2
Fig. 3. Representative profiles of apoptotic T lymphocytes of an AD and a CNT 
proband, assessed by flow cytometry. All of the histograms show only CD3-positive 
cells. The percentage of apoptotic T lymphocytes can be seen in the Ml region 
(compared to the total number of T lymphocytes).
3.2. O xidative D N A  dam age in D o w n ’s lym phocytes
In the routine hematological tests, no clinically significant differences were 
found between the DS and CNT groups as concerns the parameters examined, e.g. the 
differential and total numbers of lymphocytes.
In the basal state, as revealed in Table 4, with the exception of the number of 
SSBs, significantly and age-independently (i.e. the interactions of the groups (DS or 
CNT) and the age categories were non-significant) elevated numbers of SSBs and 
oxidized bases (pyrimidines and purines) were demonstrated in the nDNA of the 
lymphocytes in the overall DS group as compared with the healthy CNT group.
In both the stress-induced state and after the repair period, pairwise comparisons 
demonstrated markedly elevated DNA injury levels in the DS children with respect to 
the age- and gender-matched CNTs as concerns all the parameters examined (Table 5 A, 
Fig. 4). The levels of repaired SSBs and oxidized bases were similar in DS children and
the corresponding CNTs. The amounts of H202-induced and residual oxidized purines 
were significantly (p= 0.02 and 0.01, respectively) higher in the DS children than in the 
CNT children.
Surprisingly, as indicated by the results in Table 5B, in both the induced state 
and after the subsequent repair, the degrees of DNA damage were comparable in the 
lymphocytes from the DS adults and the age-matched CNTs for all parameters 
(Table 5B). The numbers of repaired SSBs and oxidized bases were similar in the adults 
with DS and the corresponding CNTs. In contrast with the children, the amounts of 
H20 2-induced and residual oxidized purines were comparable in the DS adults and in 
the CNT adults.
In all three conditions tested, the extents of DNA damage observed were greater 
in the DS children than in the DS adults, with the exception of the basal levels of SSBs 
and oxidized purines, while they were lower in the CNT children than in the CNT adults 
(Tables 5A and B). But these differences were only marginally significant or not 
significant (p=0.15-0.93 and 0.06-0.26, respectively), with the exception of the amounts 
of residual SSBs and oxidized purines in the CNT group (p=0.04), probably because of 
the relatively small number of children who participated. The extents of repaired SSBs 
and oxidized bases were similar in all four categories. Further data analysis failed to 
reveal significant differences between the children and adults in either the DS or the 
CNT groups as regards oxidized bases.
The effect of gender was not found to be statistically significant (p=0.59). The 
extent of oxidative DNA damage of the lymphocytes did not correlate with the age of 
the subjects for any of the conditions and parameters used (I r| =0.008-0.16 
\p=0.27-0.96]).
Table 4. Degree of oxidative DNA damage in lymphocytes of CNT and DS individuals 
(children and adults together)
CNT DS Significance Significance
Conditions examined (n=25) (n=25) (CNT versus DS) of interaction
% tail DNA values % tail DNA values pa value pb value
Basal SSBs 8.7 ±0.4 9.1 ±0.6 0.42 0.53
Basal SSBs + EndoIII sites 9.8 ±0.5 11.2 ±0.6 0.04 0.37
Basal SSBs + Fpg sites 11.2 ±0.5 13.2 ±0.7 0.02 0.66
Induced SSBs 26.0 ± 1.6 29.0 ± 1.2 0.04 0.07
Induced SSBs + EndoIII sites 29.0 ± 1.6 33.0 ± 1.4 0.02 0.06
Induced SSBs + Fpg sites 32.3 ± 1.6 37.5 ± 1.8 0.007 0.07
Residual SSBs (after repair) 19.0 ± 1.2 21.9 ± 1.1 0.02 0.06
Residual SSBs + EndoIII sites 21.0 ± 1.2 23.6 ± 1.2 0.02 0.02
Residual SSBs + Fpg sites 25.3 ± 1.3 29.7 ± 1.4 0.004 0.02
aTwo-way ANOVA
interaction of the groups (CNT and DS) and the age categories (children and adults)
The statistically meaningful p  values are given in italics; the others are presented for
completeness (cf. Section 2.3).
p<0.05 was considered statistically significant
DNA damage values are expressed as means ± SEM
Table 5. Degree of oxidative DNA damage in lymphocytes of CNT and DS children (A) 
and adults (B).
Pairwise comparisons were performed on estimated marginal means with the LSD
method
A
% tail DNA values in children Significance
Conditions examined CNT DS (CNT versus DS)
(n=7) (n=7) p  value
Basal SSBs 8.4 ± 0.5 9.6 ± 1.4 0.40
Basal SSBs + EndoIII sites 9.4 ± 0.4 11.9 ± 1.4 0.09
Basal SSBs + Fpg sites 10.5 ±0.3 13.1 ± 1.5 0.12
Induced SSBs 23.0+1.2 31.7 ±2.3 0.02
Induced SSBs + EndoIII sites 25.3 ± 1.2 35.7 ±2.2 0.01
Induced SSBs + Fpg sites 28.3 ± 1.8 40.7 ± 2.6 0.008
Residual SSBs (after repair) 16.0+1.3 24.0 ±2.1 0.01
Residual SSBs + EndoIII sites 17.5 ± 1.3 26.3 ±2.1 0.007
Residual SSBs + Fpg sites 21.0± 1.5 32.6 ±2.3 0.002
B
% tail DNA values in adults Significance
Conditions examined CNT DS (CNT versus DS)
(n=18) (n=18) p  value
Basal SSBs 8.8 ±0.6 9.0 ± 0.6 0.87
Basal SSBs + EndoIII sites 10.0 ±0.6 11.0 ± 1.0 0.29
Basal SSBs + Fpg sites 11.5 ±0.7 13.3 ± 1.2 0.08
Induced SSBs 27.2 ±2.1 27.9 ± 1.4 0.76
Induced SSBs + EndoIII sites 30.5 ±2.1 31.9 ± 1.7 0.58
Induced SSBs + Fpg sites 33.9 ±2.1 36.3 ±2.2 0.40
Residual SSBs (after repair) 20.2 ± 1.5 21.0 ± 1.4 0.59
Residual SSBs + EndoIII sites 22.4 ± 1.5 22.6 ± 1.4 0.91
Residual SSBs + Fpg sites 26.9 ± 1.5 28.6 ±1.7 0.62
CNT child DS child
After repair
Fig. 4. Representative images of the extents of SSBs of lymphocytes from a CNT and a 
DS child before and after the addition of H2O2, and the following repair, observed by 
means of comet assay method
4. D iscussion
4.1. A poptosis in A lzheim er’s lymphocytes
AD is the most common neurodegenerative disorder of the elderly where 
apoptotic cell death may play a role in the neuronal loss leading to dementia. However, 
these pathological processes are not limited only to the CNS, but also appear in 
non-neuronal tissues. Since there is an emerging body of evidence of increased 
apoptosis in AD in the periphery and of the ability of UVB light to trigger apoptotic cell 
death, we examined the influence of UVB (308 nm) exposure on the peripheral blood 
T lymphocytes of AD patients.
The significantly reduced susceptibility of the AD lymphocytes to apoptosis as 
compared with the CNTs in consequence of the UVB treatment was found to be 
dose-dependent. T cells from AD subjects were more resistant than those from the CNT 
group to UVB irradiation, suggesting either that these cells responded abnormally to 
UVB-induced stress or that the AD-related events could render them less sensitive. 
Under untreated, non-irradiated conditions, no significant difference was observed 
between the patient group and the age-matched, non-demented CNTs in their sensitivity 
to the UVB beam.
The comparable degrees of spontaneous apoptosis in the AD and the CNT 
groups were similar to the results obtained earlier by measuring the intracellular Ca2+ 
concentrations [122] and the in vitro production of cytokines [69]. However, following 
induction (stimulation by mitogens), the tendency of AD lymphocytes to apoptosis has 
been demonstrated to be significantly elevated [69, 122]. Previous studies, although 
differing in methodology [33, 79, 112, 122], described an increased vulnerability of 
lymphocytes to death in AD, both/either in the induced (by apoptotic stimuli) and/or in 
the non-induced cases (spontaneous apoptosis). In contrast, in our work, the greater 
sensitivity to the apoptotic stimulus was detected in the CNTs, and not in the AD group. 
Under the non-induced conditions, the two groups displayed the same levels of 
susceptibility. Accordingly, the dose-dependent difference in vulnerability of the AD 
and the CNT lymphocytes could be the explanation of our findings. The hypothesis that 
the immune system in AD may be in an “activated state” [69] seems to be in harmony 
with this assumption, postulating the presence of a protective mechanism.
Interestingly, UV light could give rise to a decreased rate of cell death in AD 
lymphocytes, an observation not in agreement with earlier results. Others noted no 
significant differences in the numbers of chromatid breaks [100] or in the viability 
ratios [107]. These were reported in the lymphocytes of DS patients too [97]. AD 
fibroblasts also exhibited a UV-induced, unscheduled DNA synthesis and removal of 
pyrimidine dimers [10, 19] as compared with those from normal subjects. A possible 
interpretation of these differences may be methodological. In our experiments, a longer 
UV light wavelength (308 nm) and higher doses (100, 200 or 300 mJ/cm2) were applied 
than in the experiments of the above authors (254 nm; 12J/m2 (=1.2 mJ/cm2) and
0.08 J/m2). Furthermore, all of them except Robbins et al. [107] investigated the 
apoptotic signals at molecular levels, whereas we examined the appearance of apoptosis. 
On the other hand, Robbins et al. [107] and Otsuka et al. [97] employed Epstein-Barr 
virus-transformed peripheral blood B lymphocytes, which are generally considered to be 
more resistant to apoptosis. However, the parameters applied in our work have 
previously been demonstrated to be efficient in inducing apoptosis in Huntington’s 
lymphocytes [53].
UVB light can cause apoptosis via various cellular signaling pathways. The 
predominant cause seems to be the induction of nDNA damage. Additionally, UVB 
exposure could activate cell surface death receptors and components of the signal 
transduction system. Moreover, UVB irradiation can induce the formation of ROS. All 
these pathways trigger the apoptotic program [65]. The DNA damage may be due to the 
upregulation of proapoptotic molecules such as p53, and the downregulation of 
antiapoptotic molecules such as Bcl-2, which is continuously produced in all peripheral 
T cells to provide resistance and to ensure survival. The expression of Bcl-2 was found 
to be higher in AD lymphocytes than in those of patients with multi-infarct dementia, 
which also correlates with the low dexamethasone sensitivity of AD lymphocytes [90]. 
Since this steroid drug has anti-inflammatory and immunosuppressive effects that are 
similar to those of UVB, this observation could be a possible explanation of our results, 
supporting the role of Bcl-2 in the UVB-induced DNA damage and in the presumption 
that the T cells of AD patients may become more resistant to stress.
Taken together, we have demonstrated a dose-dependent, reduced tendency of 
AD T lymphocytes to UVB light-induced apoptosis, suggesting at least two alternatives 
for the mechanism of cell death. Firstly, if our results reflect a deficit in apoptotic cell 
death pathways, then the decreased vulnerability must be regarded as an abnormal and 
harmful response of these cells to stress, leading to chronic inflammatory processes. 
Secondly, the lower sensitivity to UVB exposure could be considered a better response 
as a consequence of the increased activity of the immune system. This may be in 
agreement with the ongoing inflammatory events found in AD.
Although the method applied is rapid and reliable, it is expensive to use in the 
daily clinical practice, and the results observed did not promote our knowledge 
concerning the prevention or diagnosis of AD. Further experiments at a molecular level 
may be valuable to clarify these capabilities of the lymphocytes and hence their possible 
significance in the antiapoptotic treatment or immunotherapy of AD.
4.2. O xidative D N A  dam age in D o w n ’s lym phocytes
Since, lymphocytes from individuals with AD exhibited an enhanced degree of 
oxidative DNA damage [59, 82, 87], and DS serves as a unique natural human model 
with which to examine the potential role of ROS in the early development of 
pathobiochemical alterations leading to AD, we investigated the degree of oxidative 
nDNA damage in lymphocytes from children and adults with DS.
The lymphocytes from the DS children displayed enhanced DNA damage 
following OS induction as compared with the corresponding CNTs, whereas no 
difference was found between the DS adults and the age-matched CNTs. This result 
may reflect an age-dependent sensitivity of lymphocytes to in vitro H202-induced OS in 
DS, indicating that the lymphocytes are more vulnerable to OS in DS children than in 
CNT children. Moreover, our data demonstrated age-independent elevated levels of 
oxidative DNA damage of the DS lymphocytes in the basal state (Table 4), which may 
serve as further evidence of the presence of increased in vivo endogenous OS in the 
periphery, confirming that the OS is manifested throughout the whole DS organism, 
from the brain to the blood or urine [58, 88, 95, 101, 150]. This observation is similar to 
earlier ones on AD leukocytes [59, 82, 87], reinforcing the relationship between these
two disorders. The repair of the induced oxidative damage was similar in the DS and the 
CNT individuals, pointing to an age-independent repair capacity and a plausible 
difference between DS and AD as regards the rate of repair of oxidative DNA damage.
In the basal state, the numbers of SSBs and oxidized bases were found to be 
heightened in the DNA of the lymphocytes from the overall DS group as compared with 
the overall CNT group, with the exception of the number of SSBs, regardless of age 
(Table 4). To the best of our knowledge, a significantly elevated number of strand 
breaks has been reported in only a single comet assay study on lymphocytes from 
newborns with DS [74]. The discrepancy between the observations is probably due to 
methodological differences. Although the relationship between CNS and peripheral 
oxidative processes is poorly understood [84], the higher level of oxidative damage 
obtained here in DS lymphocytes in the resting condition (Table 4) may perhaps support 
the existence of enhanced systemic OS in vivo. The fact that there were no differences 
between the children and adults with DS as concerns the degrees of DNA injuries in 
these basal states may reflect a similar in vivo oxidative status of their lymphocytes.
Significantly enhanced levels of oxidative DNA damage were detected as 
regards all the parameters examined, and particularly the oxidized purines themselves, 
in both the OS-induced state and after the repair period, in the children with DS as 
compared with the age- and gender-matched CNTs (Table 5A). The extents of DNA 
damage were similar in the DS adults and the CNT adults (Table 5B), suggesting that 
the lymphocytes were more vulnerable to OS in the DS children than in the age-matched 
CNT group, although the in vivo milieu is considerably more complex than the in vitro 
conditions currently investigated.
The comparisons between the children and the adults failed to reveal marked 
differences, with the exception of the amounts of residual SSBs and oxidized purines in 
the CNT group, possibly because of the small number of children who participated in 
this cohort. Thus, our findings may indicate that young trisomic lymphocytes are more 
sensitive than older ones to OS. In harmony with this assumption, the susceptibility of 
DS lymphocytes to X-ray exposure, measured via chromosome aberrations, has been 
suggested to decrease with age [124]. Another possible interpretation of the lower 
sensitivity of the lymphocytes from the DS adults to OS may be that these cells have 
become more resistant, i.e. they are “survivor” lymphocytes selected during aging,
explaining why these DS patients could live to adulthood. The cause of this finding may 
be that the proportion of patients with chronic medical problems in the present cohort 
was much higher in the children (3/7) than in the adults (4/18).
The levels of repaired SSBs and oxidized bases were the same in the different 
age categories, which may point to the similar and age-independent repair capacity of 
such damage in DS and CNT subjects. A defective NER pathway was earlier noted in 
DS lymphocytes [104], but BER, the main repair mechanism for the handling of 
oxidative DNA damage [115], has not been studied previously. In line with reported 
observations [82, 87], in all the states examined, purines seem to be more susceptible 
than pyrimidines to oxidative damage, and their repair is slower [55].
The results here on DS subjects in part resemble those previously found for AD 
lymphocytes or leukocytes [59, 82, 87]. This similarity may be explained by the elevated 
APP content of these cells, which may correspond to generalized alterations in the 
expression or processing of APP, supposing a novel determinant for the timing of AD 
onset [98]. Likewise, as measured by the production of pro-inflammatory cytokines, 
there is a partial impairment in lymphocyte functions in both aged DS patients and 
severely demented AD individuals [99], Moreover, a decreased mitotic index of DS and 
AD lymphocytes in the presence of exogenous glutamine points to a lymphocyte 
dysfunction [102]. A reduced intracellular Ca response of mitogen-induced T cells 
from AD and older DS individuals may strengthen the possibility of a close connection 
between DS and AD [43].
Taken together, the genomic DNA of the lymphocytes from DS patients has been 
found to exhibit a damaged oxidative status, regardless of age, providing further 
evidence of enhanced endogenous OS in DS and thereby strengthening the relevance of 
antioxidant therapy of this disorder. Moreover, an inverse relationship has been 
demonstrated between age and the sensitivity to OS in the case of DS lymphocytes, but 
their DNA repair capacity remains intact. These preliminary observations may not 
contribute to prevention strategies, simply because of the reverse manner and the 
similarity, respectively. Furthermore, although the comet assay is a beneficial method at 
an individual cell level, it is perhaps too expensive and time-consuming to become a 
routine diagnostic procedure.
4.3. L im itations
The major weakness of both studies is the small sizes of the cohorts examined.
A further limitation may be the under-representation of male subjects among 
both the AD patients and the CNTs. Despite this, the results seem to be robust. 
Additionally, to the best of our knowledge, the importance of gender has not been 
revealed as concerns apoptosis.
Our observations on DS patients have some further weaknesses:
The main limitation is the small number of children involved.
Moreover, we did not look at different subsets of lymphocytes and their ratios in 
the groups examined. The metabolic and immune activities of the cells were not 
checked. It was earlier demonstrated that the CD4+ T lymphocytes are the fraction with 
the highest induced level of spontaneous genetic damage [86]. Since the extent of DNA 
fragmentation can be increased during the cell subtype isolation procedure, which is 
time-consuming and the results of which are prone to artifacts [81], we decided not to 
subfractionate the cells in our experiment.
Furthermore, we did not assess dementia-related neuropsychological parameters 
in our adult DS patients, and we therefore cannot determine any connections as regards 
the existence and degree of dementia, for example. Most studies have shown that the 
onset of clinical dementia (if it develops [149]) occurs between the ages of 40 and 60 
years [70] (mean age 56 years [135]), but only one participant fell within this interval in 
the present cohort.
Finally, the comet assay procedure allows only an overall picture of DNA 
oxidation, and we looked at nDNA, which is less extensively oxidized than 
mtDNA [142].
5. Sum m ary
I. 1. It has been found that UVB radiation could induce apoptosis in
T lymphocytes from AD and CNT individuals, confirming the observations of previous 
papers.
2. We have demonstrated a decreased level of apoptosis in T lymphocytes 
from AD patients to UVB light induction relative to CNT subjects, indicating either a 
defective apoptotic pathway or a better response of these cells to stress.
3. It has been reported that the extent of cell death was dose-dependent in both 
the AD and CNT lymphocytes: larger doses triggered greater degrees of apoptosis, with 
the exception of the largest dose applied.
II. 1. Our data demonstrated elevated levels of basal oxidative damage of nDNA 
of lymphocytes from the DS subjects as compared with the CNTs, regardless of age, 
providing further evidence of the presence of increased in vivo endogenous OS in the 
periphery in DS.
2. The lymphocytes from the DS children exhibited elevated DNA damage 
following OS induction as compared with the corresponding CNTs, whereas no 
difference was found between the DS adults and the age-matched CNTs, reflecting an 
age-dependent sensitivity of the lymphocytes to in vitro H202-induced OS in DS.
3. The repair of the induced oxidative damage was similar in all the DS and 
the CNT individuals, pointing to an age- and disease-independent repair capacity.
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